Finance

Beta
Lists
AORT:NYSE
Artivion Inc
$20.84
+1.26%
(+0.26) 1D
$20.84
0.00% (0.00)
After hours
Closed: Jun 4, 4:00:07 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AORT...
Open
$21.00
High
$21.61
Low
$20.63
Mkt. cap
1.01B
Avg. vol.
754.22K
Volume
1.01M
P/E ratio
87.17
52-wk high
$48.25
52-wk low
$19.16
EPS
$0.24
Beta
1.26
Shares outstanding
48.54M
No. of employees
2K
Open
$21.00
High
$21.61
Low
$20.63
Mkt. cap
1.01B
Avg. vol.
754.22K
Volume
1.01M
P/E ratio
87.17
52-wk high
$48.25
52-wk low
$19.16
EPS
$0.24
Beta
1.26
Shares outstanding
48.54M
No. of employees
2K
Analyst outlook
Analyst Ratings
Based on 7 analysts giving stock ratings to AORT in the past 3 months
Strong Buy
Buy
7
Hold
0
Sell
0
12 month forecast
Based on 7 Wall Street analysts offering 12 month price targets for AORT in the last 3 months.
Highest
Current $20.84
$48.00 (+130.33%)
Average
$42.57 (+104.27%)
Lowest
$36.00 (+72.74%)
News stories
From sources across the web
Profile
Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive. Wikipedia
About Artivion Inc
CEOJames Patrick Mackin
Employees1.8K
Founded1984
HeadquartersKennesaw, Georgia, United States
SectorMedical device
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.08 / $0.12
-35.13%miss
Revenue / Est. (USD)
116.34M / 115.69M
+0.56%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
112.97M
113.39M
115.99M
116.34M
Cost of goods sold
39.86M
38.99M
42.85M
40.89M
Cost of revenue
39.86M
38.99M
42.85M
40.89M
Research and development expenses
7.06M
8.08M
9.12M
8.84M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
55.06M
54.68M
54.64M
60.58M
Operating expense
62.13M
62.76M
63.76M
69.42M
Total operating expenses
101.99M
101.75M
106.61M
110.31M
Operating income
10.98M
11.64M
9.38M
6.03M
Other non operating income
464.00K
499.00K
1.18M
514.00K
EBT including unusual items
3.48M
7.06M
6.54M
339.00K
EBT excluding unusual items
8.75M
6.16M
5.15M
579.00K
Income tax expense
2.14M
554.00K
4.11M
-1.08M
Effective tax rate
61.37%
7.85%
62.89%
-317.99%
Other operating expenses
-
-
-
-
Net income
1.34M
6.50M
2.43M
1.42M
Net profit margin
1.19%
5.73%
2.09%
1.22%
Earnings per share
0.24
0.16
0.17
0.08
Interest and investment income
68.00K
240.00K
311.00K
205.00K
Interest expense
-7.27M
-6.12M
-5.62M
-5.37M
Net interest expenses
-7.20M
-5.88M
-5.31M
-5.16M
Depreciation and amortization charges
-
-
-
-
EBITDA
16.52M
17.35M
15.14M
12.37M
Gain or loss from assets sale
-
-3.50M
-3.50M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more